Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.61 |
| ▸ | UMPS | P11172 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formycin SCHEMBL14074914 | 1.00 | HIF1A (0.61) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| Formycin SCHEMBL15262901 | 1.00 | HIF1A (0.61) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| SCHEMBL22399466 | 0.90 | HIF1A (0.50) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| Formycin SCHEMBL28203182 | 0.88 | HIF1A (0.50) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| SCHEMBL5071998 | 0.86 | HIF1A (0.48) | HIF1AUMPSSTAT6SMN1; SMN2SLC29A1 | |
| SCHEMBL866845 | 0.82 | ATG7 (0.51) | — | |
| SCHEMBL18522114 | 0.81 | HIF1A (0.41) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| SCHEMBL22381816 | 0.81 | HIF1A (0.41) | HIF1AUMPSGAPDHADORA3SLC28A2 | |
| Formycin SCHEMBL10149284 | 0.80 | HIF1A (0.55) | HIF1AGAPDHADORA3SLC28A2DPP4 | |
| Formycin SCHEMBL4196088 | 0.80 | HIF1A (0.55) | HIF1AGAPDHADORA3SLC28A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334745-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334745-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017027646-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-8871735-B2 | Methods and compositions for providing cardiac protection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130131005-A1 | METHODS AND COMPOSITIONS FOR PROVIDING CARDIAC PROTECTION | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110021453-A1 | Methods and compositions for providing cardiac protection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2011-01-27 | — | — | US | disclosed |
| WO-2009099676-A1 | TYPE 5 ADENYLYL CYCLASE INHIBITORS FOR PROVIDING CARDIAC PROTECTION | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2009-08-13 | — | — | WO | disclosed |
| US-7368437-B1 | Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents | BAYER CROPSCIENCE AG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1165563-B1 | BICYCLIC HETEROCYCLES, METHOD FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PHARMACEUTICAL AGENTS | BAYER CROPSCIENCE GMBH (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-4028184-A | CULTURING CORYNEBACTERIUM, ARTHROBACTER, MICROBACTERIUM | KIKKOMAN SHOYU CO., LTD. (JA) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-11453697-B1 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | HIF1A 2562/4885UMPS 604/4885GAPDH 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.